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ABSTRACT
The invasion-promoting MT1-MMP is a cell surface-associated collagenase with 
a plethora of critical cellular functions. There is a consensus that MT1-MMP is a key 
protease in aberrant pericellular proteolysis in migrating cancer cells and, accordingly, 
a promising drug target. Because of high homology in the MMP family and a limited 
success in the design of selective small-molecule inhibitors, it became evident that the 
inhibitor specificity is required for selective and successful MT1-MMP therapies. Using 
the human Fab antibody library (over 1.25×109 individual variants) that exhibited 
the extended, 23-27 residue long, VH CDR-H3 segments, we isolated a panel of the 
inhibitory antibody fragments, from which the 3A2 Fab outperformed others as a 
specific and potent, low nanomolar range, inhibitor of MT1-MMP. Here, we report 
the in-depth characterization of the 3A2 antibody. Our multiple in vitro and cell-
based tests and assays, and extensive structural modeling of the antibody/protease 
interactions suggest that the antibody epitope involves the residues proximal to the 
protease catalytic site and that, in contrast with tissue inhibitor-2 of MMPs (TIMP-2), 
the 3A2 Fab inactivates the protease functionality by binding to the catalytic domain 
outside the active site cavity. In agreement with the studies in metastasis by others, 
our animal studies in acute pulmonary melanoma metastasis support a key role of 
MT1-MMP in metastatic process. Conversely, the selective anti-MT1-MMP monotherapy 
significantly alleviated melanoma metastatic burden. It is likely that further affinity 
maturation of the 3A2 Fab will result in the lead inhibitor and a proof-of-concept for 
MT1-MMP targeting in metastatic cancers.
INTRODUCTION
Metastatic spread is frequently lethal to cancer 
patients and the treatment options are frequently limited. 
In multiple cancer types, the level of zinc-dependent 
matrix metalloproteinases (MMPs) is increased to allow 
metastatic cells to degrade the extracellular matrix and to 
invade the tissue and distant organs [1-5].
There are 23 individual MMPs in humans from 
which 18 proteinases are soluble and 6 are membrane-
tethered [membrane type (MT)-MMPs] [6]. Soluble 
MMP proenzymes typically contain an N-terminal 
inhibitory prodomain followed by a catalytic domain 
(CAT), a flexible hinge linker and a hemopexin domain 
[7]. In addition, MT-MMPs also includes either a 
transmembrane domain followed by a cytoplasmic tail 
domain (MT1-, MT2-, MT3- and MT5-MMP) or a 
glycosylphosphatidylinositol moiety (MT4- and MT6-
MMP) that tethers these proteases to the cell membrane 
[7]. MMPs are zinc-dependent proteinases and they share 
the active site zinc binding motif HEXXHXXGXXH in 
which the His residues coordinate the catalytic zinc ion 
[8]. MMPs are synthesized as latent zymogens that require 
proteolytic activation to become functional proteases. 
In this process, the N-terminal inhibitory prodomain is 
removed and the catalytic site of the emerging mature 
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enzyme becomes liberated and exposed. It is established 
that pro-metastatic, collagenolytic membrane-tethered 
MT1-MMP/MMP-14 functions as a main mediator of 
the pro-migratory proteolytic events at the cell surface 
[9, 10]. Expression of MT1-MMP directly correlates with 
poor clinical outcome, blood vessel invasion and high 
incidence of distant metastasis in multiple cancer types 
[11-13]. MT1-MMP null mice are dwarfs with skeletal 
abnormalities and soft tissue disorders, and they die prior 
to adulthood, thus supporting the crucial function of MT1-
MMP in cell migration during gastrulation and collagen 
turnover [14]. Overall, there is a consensus among 
researchers that because of its importance in promoting 
cell invasion and metastasis MT1-MMP is a promising 
drug target in cancer and certain other pathologies [11-13, 
15-19].
MT1-MMP is regulated both as a protease and as a 
membrane-anchored protein. Similar with other MMPs, 
the proteolytic removal of the inhibitory prodomain 
is required for the conversion of the latent, 63 kDa, 
MT1-MMP zymogen into the functionally active, 55 
kDa, protease. The furin-like proprotein convertase 
activity is essential to the prodomain removal and 
MT1-MMP activation [20-22]. Once activated, MT1-
MMP can be efficiently inhibited by its natural protein 
inhibitors, tissue inhibitors of MMPs (TIMPs) [23]. 
The binding of TIMPs to the MT1-MMP active enzyme 
results in the stoichiometric and proteolytically inactive 
TIMP•MT1-MMP complex. There are four individual 
TIMPs in humans (TIMP-1, -2, -3, and -4) [23, 24]. 
With the exception of TIMP-1, TIMPs are efficient, sub-
nanomolar inhibitors of MT1-MMP [25, 26]. The MT1-
MMP/TIMP balance is arguably the most significant 
factor in the regulation of the net proteolytic activity of 
cellular MT1-MMP. As a membrane-tethered protease, 
MT1-MMP is also regulated via cellular compartment 
trafficking, internalization and recycling [4, 27, 28]. These 
coordinated, multi-dimensional mechanisms regulate 
MT1-MMP spatially and temporally, and they concentrate 
the MT1-MMP activity on the leading and trailing edges 
in migrating cells [10].
Through earlier trial and error, it became evident 
that the inhibitor specificity is required for selective and 
successful MMP therapies [29-33]. Accomplishing the 
required target specificity and selectivity with small-
molecule MMP inhibitors is exceedingly difficult 
and so far the success has been limited. Because the 
catalytic mechanism and the catalytic domain fold are 
largely conserved in the MMP family members, the 
small-molecule inhibitors simultaneously interact with 
multiple MMPs resulting in off-target effects and low 
therapeutic efficacy [31-33]. As a viable alternative and 
because of their potentially supreme selectivity, a few 
human recombinant inhibitory antibodies are emerging 
as both research tools and promising therapeutic agents 
[34-36]. Among the currently developed anti-MT1-
MMP antibodies [17, 34, 37-41], the human recombinant 
monoclonal DX2400 IgG is the most potent and selective 
inhibitory antibody raised against human MT1-MMP 
(Ki = 0.6 nM) [36].
We hypothesized that the antibodies that efficiently 
inhibit MT1-MMP should resemble TIMP-2 (the 
natural, most potent MT1-MMP inhibitor). TIMP-2 
exhibits a long, convex-shaped loop that inserts into the 
protease active site and blocks the catalytic function 
[42, 43]. Accordingly, we suggested that the paratope/
complementarity determining regions (CDRs) of a MT1-
MMP-inhibitory antibody should be flexible and long 
enough to access the active site cavity. We then custom-
designed synthetic human Fab libraries carrying a 23-
27 residue long and flexible heavy chain (VH) CDR-H3 
paratope that was inserted into the human antibody 
framework. Here, we characterize a novel, selective and 
potent, human recombinant 3A2 MT1-MMP antibody 
identified in our hybrid Fab antibody library [43]. The 
unique methodology we used in designing and selecting 
this inhibitory antibody is described in our accompanying 
manuscript (submitted). Our results support and extent 
the investigations by others. Our current observations 
demonstrate the importance of MT1-MMP in promoting 
the metastatic process. Conversely, the selective anti-MT1-
MMP monotherapy is likely to alleviate the melanoma 
metastatic burden and, ultimately, to perform similarly 
in certain other metastatic cancers with the enhanced 
expression and activity of MT1-MMP.
RESULTS
The 3A2 Fab is an efficient inhibitor of MT1-
MMP
We synthesized the human Fab antibody library 
(over 1.25×109 individual variants) that exhibited the 
extended, 23-27 residue long, VH CDR-H3 segments 
(submitted). These Fab constructs were expressed in E. 
coli, purified from the E. coli cell lysates and the purified 
samples (purity >95%) were then used in our studies. We 
next identified over twenty binders from which fourteen 
performed as potent inhibitors of MT1-MMP. In our 
current study, four of the most efficient Fab antibody 
binders of MT1-MMP were then selected for the in-depth 
analysis and characterization (Figure 1A).
Using the Fab ELISA tests with the individual 
catalytic domain of MT1-MMP (MT1-CAT) as bait 
for the increasing concentrations of the Fab fragments, 
we confirmed that the 3A2 (VH CDR-H3 sequence 
VKLQKDKSHQWIRNLVATPYGRYVMDY), 2B5 (VH  
CDR-H3 sequence IGVNAWAVKMSQRMLATRGSGWY 
VMDY) and 3E9 (VH CDR-H3 sequence NGRY 
PGFLKRAHKRLLNFKAYVMDY) Fab fragments 
efficiently bound to MT1-MMP, while the 3B10 
Fab (VH CDR-H3 sequence ALPRKRVMVARRP 
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PWNGRWVKLYGMDY) was far less efficient in our 
ELISA binding tests. The Kd value of the 3A2 Fab (8 nM) 
was comparable with that of the DX2400 Fab (2 nM; VH 
CDR-H3 sequence GRAFDI), which is currently the most 
potent inhibitory antibody developed against human MT1-
MMP [35, 36] (Figure 1B). Our additional cleavage tests 
using the Mca-PLGL-Dpa-AR-NH2 peptide as a cleavage 
substrate and the increasing concentrations of the Fab 
fragments as inhibitors revealed that both the 2B5 and 
3A2 Fab antibodies performed as efficient, low nanomolar 
range, antagonists of MT1-MMP. Thus, the IC50 value of 
the 3A2 Fab was 18 nM, suggesting that this Fab sequence 
is only 2-fold less efficient against MT1-MMP compared 
with the DX2400 Fab (8.5 nM). In turn, neither the 3B10 
nor 3E9 Fab fragments inhibited MT1-MMP activity (IC50 
> 5,000 nM for both) indicating that the binding efficacy 
does not always directly correlate with the inhibitory 
potency (Figure 1C).
The 3A2 Fab performs as a selective inhibitor of 
MT1-MMP
To test if the 3A2 antibody performs not only as 
an efficient but also as a selective inhibitor, we evaluated 
Figure 1: The 3A2 Fab is a selective, low nanomolar inhibitor of MT1-MMP. A. The clone, the sequence and the length of 
the CDR-H3 region in the selected Fab binders of MT1-MMP. B. Fab ELISA with the selected Fab binders of MT1-MMP. Left, the biotin-
labeled catalytic domain of MT1-MMP (MT1-CAT) was captured onto streptavidin-coated wells of a 96-well plate. The Fab antibodies 
(0-8,000 nM) were allowed to bind to MT1-CAT. The bound antibodies were detected using HRP-conjugated anti-human Fab and a 
TMB/E substrate. Data are means ± SE from three individual experiments performed in triplicate. Right, the Kd values were calculated 
from the reactions in which a half of MT1-CAT was complexed with the added Fab. C. Inhibition of the MT1-MMP cleavage activity 
by the selected Fab antibodies. Left, the dose-response inhibition by the Fab fragments. The cleavage activity of MT1-CAT (5 nM) was 
measured in the presence of the increasing concentrations of the Fab antibodies (0-5,000 nM) using a Mca-PLGL-Dpa-AR-NH2 substrate 
(1 µM). The residual cleavage activity was expressed in percent relative to a “no Fab” control. Data are means ± SE from 3 individual 
experiments conducted in triplicate. Right, the IC50 values for the selected Fab antibodies. *
a and *b, the weak inhibitory and non-inhibitory 
Fabs, respectively. D. The 3A2 Fab antibody is a selective inhibitor of MT1-MMP. The individual CAT of MT-MMPs (5 nM, each) were 
co-incubated with the increasing concentrations of the 3A2 Fab antibody (0-5,000 nM). The residual cleavage activity was measured using 
a Mca-PLGL-Dpa-AR-NH2 substrate (1 µM). Left, the representative dose-response curves of the 3A2 Fab antibody against MT1-CAT. 
Right, the IC50 values of the 3A2 Fab antibody in the individual MT-MMPs. RFU, relative fluorescence unit; *
c, no inhibition at the highest 
Fab concentration used. E. The 3A2 Fab antibody inhibits MT1-MMP proteolysis of AAT. AAT (2 μM) was co-incubated with MT1-CAT 
alone (40 nM, no inhibitor) or jointly with the 3A2 or DX2400 Fab fragments (20 and 200 nM, each), TIMP-1 (1,000 nM), TIMP-2 (20 nM) 
or GM6001 (1,000 nM). The reactions were analyzed by SDS-PAGE followed by Coomassie staining. DX, DX2400.
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its off-target interactions against a panel of the purified 
MMPs. Because earlier we have already proved that the 
3A2 antibody did not cross-react with the soluble MMP-
2 and MMP-9 (submitted), here we evaluated the more 
closely related enzymes from the MT-MMP sub-family, 
including MT2-MMP, MT3-MMP, MT4-MMP, MT5-
MMP and MT6-MMP. For these purposes, the increasing 
concentrations of the 3A2 Fab were used to inhibit the 
cleavage activity of these five MT-MMPs against the 
Mca-PLGL-Dpa-AR-NH2 substrate. Our results clearly 
indicated that the 3A2 Fab was highly specific against 
MT1-MMP (IC50 = 18 nM). The 3A2 Fab was incapable 
of inhibiting MT4-MMP and MT6-MMP (IC50 > 5,000 nM 
for both), the proteases that are less related to MT1-MMP. 
An insignificant inhibitory efficacy of the 3A2 Fab was 
observed against MT2-MMP (IC50 ≈ 1,800 nM), MT3-
MMP (IC50 ≈ 335 nM) and MT5-MMP (IC50 ≈ 425 nM) 
(Figure 1D).
Inhibition of MT1-MMP proteolysis of α1-
antitrypsin serpin by the 3A2 Fab
Because the 3A2 Fab outperformed other Fab 
constructs, our further studies were focused on the 3A2 
antibody alone. The 3A2 Fab was efficient not only in 
suppressing the peptide cleavage by MT1-MMP but also 
MT1-MMP proteolysis of the protein substrates. Thus, 
human α1-antitrypsin (AAT) serpin is a clinically relevant 
protein target of MMP proteolysis as well as a common 
and convenient substrate for testing the functional 
activity of MMPs in vitro. MMPs normally cleave the 
56 kDa AAT near the C-terminus to generate the 52 kDa 
N-terminal and the 4 kDa C-terminal fragments [44-48]. 
In agreement, at a 1:50 enzyme-substrate molar ratio, 
MT1-CAT almost fully proteolyzed AAT in 1 h. Inhibition 
of MT1-MMP proteolysis was already observable at the 
low, 20 nM, concentration of the 3A2 antibody. A 200 
nM 3A2 Fab concentration caused an almost quantitative 
inhibition of MT1-MMP proteolysis of AAT. Similar 
results were also observed with the DX2400 Fab (Figure 
1E). As controls, we co-incubated AAT with TIMP-1 
(an inefficient MT1-MMP inhibitor), TIMP-2 (a potent 
MT1-MMP inhibitor) or the broad spectrum hydroxamate 
MMP inhibitor GM6001 (IC50 = 0.4 nM against MT1-
MMP). As expected, both TIMP-2 (20 nM) and GM6001 
(100 nM) readily abolished MT1-MMP proteolysis of 
ATT, whereas TIMP-1 (1,000 nM) was without effect. 
In sum, under our experimental conditions the 3A2 Fab 
inhibitory potency was similar with that of both TIMP-2 
and DX2400 Fab.
The 3A2 Fab inhibits the functional activity of 
cellular MT1-MMP
Cellular MT1-MMP is a single physiological 
activator of the soluble MMP-2 proenzyme [49]. In the 
proMMP-2 activation pathway, MT1-MMP cleaves the 
Asn37-Leu38 scissile bond in the proMMP-2 prodomain 
sequence. This cleavage transforms the MMP-2 zymogen 
into the 64 kDa activation intermediate. The latter then 
autolytically generates the 62 kDa mature enzyme 
[49, 50]. To elucidate if the 3A2 antibody inhibits the 
functional activity of cellular MT1-MMP, we co-incubated 
human fibrosarcoma HT1080 cells that express naturally 
MT1-MMP with the 3A2 Fab for 16-18 h. For comparison, 
HT1080 cells were also co-incubated with TIMP-1, TIMP-
2 or either the DX2400 Fab or IgG. The non-inhibitory 
MT1-MMP 3G4 antibody was used as an irrelevant 
antibody control. GM6001 hydroxamate was used as an 
additional control. To increase the MT1-MMP cellular 
activity, HT1080 cells were stimulated with phorbol 
12-myristate 13-acetate. Conditioned medium aliquots 
were then analyzed by gelatin zymography. As expected, 
primarily the 68 kDa proMMP-2 zymogen was revealed 
in the intact HT1080 cells, while the significant levels 
of the 64 kDa activation intermediate and the 62 kDa 
mature enzyme of MMP-2 were present in the stimulated 
HT1080 cells (Figure 2A). Both GM6001 (1,000 nM) 
and TIMP-2 (100 nM) blocked the proMMP-2 activation 
in the stimulated HT1080 cells, while TIMP-1 (a poor 
inhibitor of MT1-MMP) and a non-inhibitory MT1-MMP 
3G4 antibody were both ineffective (1,000 nM, each). 
Our quantification of the zymogen:activation intermediate 
ratio in the MMP-2 samples demonstrated a comparable 
inhibitory efficacy of the 3A2 and DX2400 Fab fragments 
(Figure 2A).
To corroborate these data and demonstrate that 
the inhibition of MMP-2 activation was caused by the 
inactivation of cellular MT1-MMP rather than by the 
antibody cytotoxicity, we determined if the MT1-MMP 
antibodies affected cell viability. For these purposes, 
we used normal mammary epithelial 184B5 cells which 
are more fragile compared with the apoptosis-resistant 
cancer cells. Cells were incubated for 24 h with a high, 
1 µM, concentration of the antibodies. Viable cells were 
then assessed using an ATP-Lite assay. Our data clearly 
demonstrated that none of the inhibitory antibodies had an 
effect on cell viability (Figure 2B).
3A2 Fab inhibits collagenolysis mediated by 
cellular MT1-MMP
Because MT1-MMP is a collagenase, we next 
tested if the 3A2 Fab was capable of inhibiting the 
collagenolytic activity of cellular MT1-MMP. For these 
purposes, we performed a type-I collagen (COL-I) 
degradation assay using 184B5-MT1 cells and assessed 
the 3A2 inhibitory potency in comparison with that of 
GM6001, TIMP-1, TIMP-2, and both DX2400 Fab and 
IgG. As an additional control, we used 184B5-mock 
cells, which do not express MT1-MMP and, as a result, 
do not proteolyze COL-I. Cells were plated for 5 days 
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onto slides coated with COL-I, then fixed, stained with 
Coomassie and observed using a microscope. 184B5-
MT1 cells readily degraded COL-I, while 184B5-mock 
cells were negative. Both GM6001 (1,000 nM) and 
TIMP-2 (100 nM) blocked COL-I degradation in 184B5-
MT1 cells, while TIMP-1 (1,000 nM) was inactive 
suggesting that MT1-MMP rather than other MMPs was 
a key in COL-I cleavage in our cell system. Consistently, 
the 3A2 Fab (200 nM) and both the DX2400 Fab (200 
nM) and IgG (100 nM) quantitatively inhibited MT1-
Figure 2: The 3A2 Fab antibody inhibits the functional activity of cellular MT1-MMP. A. The 3A2 Fab and the DX2400 
Fab and IgG antibodies inhibited activation of the proMMP-2 zymogen by cellular MT1-MMP in HT1080 cells. Top, to induce proMMP-2 
activation, cells were stimulated using phorbol 12-myristate 13-acetate (PMA; 50 ng/ml). Cells were then co-incubated with the 3A2 and 
DX2400 antibodies (20-200 nM, each) and also with the non-inhibitory MT1-MMP 3G4 IgG antibody (20-200 nM), TIMP-1 (1,000 nM), 
TIMP-2 (100 nM) and GM6001 (1,000 nM) controls. Medium aliquots were next analyzed by gelatin zymography to identify the status 
of MMP-2. Cells alone, no inhibitors were added to the cells. Bottom, the digitized zymogen:activation intermediate ratio in the MMP-
2 samples. White and grey rectangles, zymogen and activation intermediate, respectively. The numbers indicate the percentage of the 
activation intermediate relative to the total combined amount of the zymogen and the intermediate. B. The 3A2 Fab and the DX2400 Fab 
and IgG do not affect cell viability. Normal mammary epithelial 184B5 cells were incubated alone (cells alone) or co-incubated with the 
antibodies (1,000 nM, each). Cell viability was measured using a luminescent ATP-Lite assay. Data are means ± SE from three individual 
experiments performed in triplicate. C. The 3A2 Fab antibody inhibits COL-I degradation by cellular MT1-MMP. MT1-MMP-deficient 
184B5-mock and MT1-MMP-overexpressing 184B5-MT1 cells were plated onto COL-I layers and then incubated alone or co-incubated 
for 5 days with the 3A2 Fab (200 nM), DX2400 Fab or IgG (200 nM and 100 nM, respectively), TIMP-1 (1,000 nM), TIMP-2 (100 nM) 
or GM6001 (1,000 nM). After the removal of cells, COL-I was stained with Coomassie. The representative images from three independent 
experiments performed in triplicate are shown. D. Cell invasion through COL-I. 184B5-mock (mock) and 184B5-MT1 (MT1) cells (1×105, 
each) were allowed to migrate alone (no inhibitor) or in the presence of the 3A2 or DX2400 Fab fragments (500 nM, each) or the indicated 
concentrations DX2400 IgG. GM6001 (1,000 nM) and 10% FBS were used as a control and a chemoattractant, respectively. Migration 
efficiency was calculated relative to MT1 cells, no inhibitor and 10% FBS (=100%). Data are means ± SE from three individual experiments 
conducted in triplicate. **, P < 0.05. DX, DX2400.
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MMP-dependent collagenolysis in 184B5-MT1 cells 
(Figure 2C).
3A2 Fab inhibits MT1-MMP-dependent cell 
invasion
Because cellular MT1-MMP plays a major role in 
promoting cell invasion, we evaluated if the 3A2 antibody 
was capable of affecting cell invasion through a layer 
of COL-I. For these purposes, we performed a COL-I 
invasion assay using Boyden migration chambers in which 
porous membranes were coated with a thin layer of COL-I. 
In the assay we used 184B5-MT1 cells and evaluated 
the 3A2 Fab inhibitory potency in comparison with that 
of both the DX2400 Fab and IgG antibodies. The cells 
were plated in serum-free DMEM in the upper chamber. 
DMEM-10% FBS was added to the lower chamber as 
a chemoattractant. The inhibitors were added to both 
chambers. The 184B5-mock cells that do not produce 
MT1-MMP and, as a result, do not migrate efficiently 
serve as a control [51, 52]. In turn, 184B5-MT1 cells 
stably transfected with MT1-MMP acquired an ability to 
migrate through COL-I (Figure 2D). GM6001 (1,000 nM) 
blocked migration of 184B5-MT1 cells to a level observed 
in MT1-MMP-deficient 184B5-mock cells. There was a 
noticeable repression of migration efficiency of 184B5-
MT1 cells in the presence of the 3A2 and DX2400 Fab 
fragments (500 nM each). The full-length DX2400 IgG, 
however, exhibited in a dose-dependent manner a more 
efficient inhibition suggesting that the Fab fragments 
underperform in comparison with the respective full-
length antibody format.
3A2 Fab inhibits cellular murine MT1-MMP
Because our animal studies involve mice and 
because there is a four residue difference in the MT1-CAT 
peptide sequence in mice versus humans (Supplementary 
Figure S1), we determined if the anti-human 3A2 Fab 
was species-specific. For these purposes, we performed 
the MMP-2 activation assay using murine melanoma 
B16F1 cells with the enforced expression of murine 
MT1-MMP (B16F1-mMT1 cells). Because B16F1 cells 
do not express MMP-2 naturally, the purified proMMP-2 
zymogen was added to the serum-free DMEM. Cells were 
then incubated in this medium with or without the 3A2 
or DX2400 Fab antibodies. Medium aliquots were then 
analyzed by gelatin zymography. The conversion of the 
68 kDa proMMP-2 into the 64 kDa activation intermediate 
and the 62 kDa mature enzyme was readily observed in 
the untreated B16F1-mMT1 cells (Figure 3A). Both the 
3A2 and DX2400 Fab fragments, in a dose-dependent 
manner, inhibited cellular murine MT1-MMP and blocked 
MMP-2 activation. We also confirmed that the 3A2 and 
DX2400 antibodies did not affect the viability of B16F1-
mMT1 cells (data not shown).
To corroborate these results, we tested if the 3A2 
antibody was capable of inhibiting COL-I degradation by 
the cellular murine MT1-MMP. For these purposes, we 
plated murine B16F1-mMT1 cells onto slides coated with 
COL-I and then incubated the cells with or without the 
3A2 Fab, the DX2400 Fab or IgG, TIMP-2 or GM6001. 
In 5 days, cells were removed and the slides were fixed, 
stained using Coomassie and observed using a microscope. 
Intact B16F1-mMT1 cells readily degraded COL-I layer. 
On a contrary, there was no significant degradation of 
COL-I in cells co-incubated with GM6001 (1,000 nM), 
TIMP-2 (100 nM) or the DX2400 antibody either in 
Fab or IgG format (200 nM and 100 nM, respectively) 
(Figure 3B). Overall, our data indicated that similar with 
human MT1-MMP both the 3A2 and DX2400 antibodies 
performed as potent inhibitors of the murine protease.
3A2 Fab reduces pulmonary melanoma 
metastasis in mice
We next evaluated the potency of the 3A2 Fab in 
reducing the pulmonary metastasis in the experimental 
melanoma metastasis model in mice. We specifically 
selected B16F1 cells for our in vivo studies because of 
their high metastatic propensity. To specifically focus 
on the MT1-MMP function in metastasis, we employed 
the B16F1-mMT1 cells with the enforced expression of 
murine MT1-MMP and the respective control B16F1-
mock cells transfected with the original plasmid alone.
Multiple assays confirmed the overexpression of 
the functionally active MT1-MMP in B16F1-mMT1 
relative to the B16F1-mock cell control. Thus, high level 
of MT1-MMP in B16F1-mMT1 cells was detected in cell 
extracts analyzed by Western Blotting with the MT1-MMP 
3G4 antibody (Figure 4A). Gelatin zymography analysis 
of medium aliquots demonstrated that B16F1-mMT1 
cells, but not the B16F1-mock control, were capable of 
efficiently activating MMP-2 (Figure 4A). Finally, the 
fluorescent MP-3653 reporter (a liposome tagged with a 
fluorochrome and functionalized with a PEG-5000 chain 
spacer linked to an inhibitory hydroxamate warhead) that 
binds to the active cellular MT1-MMP alone and that 
does not interact with the MT1-MMP proenzyme nor 
the catalytically inactive MT1-MMP enzyme•TIMP-2 
complex [53], readily highlighted B16F1-mMT1 cells 
but not the control cells (Figure 4A). Based on these 
tests, we concluded that the control B16F1-mock cells 
were deficient in MT1-MMP, while the stably transfected 
B16F1-mMT1 cells overexpressed this membrane 
protease.
In our animal tests, B16F1-mMT1 cells were 
injected i.v. at day 1 into athymic nude mice (n=12, 
mMT1 mice). Mice injected with B16F1-mock cells 
(n=6, mock mice) served as a control. Six mice from the 
mMT1 group received five injections of the 3A2 Fab i.p. 
(10-15 mg/kg at day 1, 3, 5, 8 and 12) (Figure 4B). Six 
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other mMT1 mice and the mock mice (n=6) received 
an injection i.p of vehicle alone. Additional three mice 
were left intact and did not receive cells nor the antibody. 
At day 23, mice were euthanized, and their lungs were 
surgically removed, weighed and photographed (Figure 
4C and 4D, Supplementary Figure S2A-S2C). Western 
blotting analysis of the tissue extract confirmed the 
continuing expression of MT1-MMP in the lungs 
from both the mMT1 and mMT1+3A2 animal groups. 
In turn, the lungs of the intact and mock mice did not 
exhibit any noticeable levels of MT1-MMP. Because of 
the massive melanoma lesions, the lung weight in the 
mMT1 group (0.717 ± 0.160 g) greatly exceeded that 
in the mock animals (0.239 ± 0.047 g) and the intact 
Figure 3: The 3A2 Fab antibody inhibits the functional activity of murine MT1-MMP. A. Murine melanoma B16F1-mMT1 
cells stably transfected with murine MT1-MMP were co-incubated with the purified proMMP-2 zymogen alone (cells alone; 5-10 nM) or 
jointly with the 3A2 or DX2400 Fab antibodies (25-200 nM each; top and bottom panels, respectively). Where indicated, GM6001 (1,000 
nM) was added to the cells. Medium aliquots were next analyzed by gelatin zymography to identify the status of MMP-2. B. The 3A2 Fab 
antibody inhibits COL-I degradation by murine cellular MT1-MMP. B16F1-mMT1 cells were plated onto COL-I layers and then incubated 
alone (no inhibitor) or co-incubated for 5 days with the 3A2 Fab (200 nM), DX2400 Fab and IgG (200 nM and 100 nM, respectively), and 
GM6001 (1,000 nM). After the removal of cells, COL-I was stained with Coomassie. The representative images from three independent 
experiments performed in triplicate are shown. DX, DX2400.
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mice (0.175 ± 0.023 g). In agreement, the number of 
metastatic nodules in the mMT1 group (198 ± 31) was 
approximately 4-fold higher relative to the mock control 
(55 ± 10). Furthermore, the nodules were bigger in 
size in the mMT1 mice relative to the control animals 
(Supplementary Figure S2A-S2B). In general, these 
observations agree well with the results by others [12, 
13, 19] and support the pro-metastatic role of MT1-
MMP in cancer. Importantly, the 3A2 antibody injections 
significantly reduced the lung weight (0.328 ± 0.123 g) 
and both the number (95 ± 28) and the size of metastatic 
lesions in mice from the mMT1+3A2 group when 
compared with the untreated mice from the mMT1 group 
(Figure 4D, Supplementary Figure S2B-S2C), making 
these parameters similar to those we recorded in the 
MT1-MMP-deficient mock control.
3A2 Fab, DX2400 Fab and TIMP-2 compete for 
the binding to MT1-MMP
The 3A2 Fab contained the 27-residue long, flexible 
VH CDR-H3 to mimic the convex-shaped loop of TIMP-2 
that interacts with the active site of MT1-MMP [54, 55]. 
To elucidate the mechanism of MT1-MMP inhibition 
by the 3A2 antibody and identify the 3A2 epitope, we 
determined if there was an overlap of the TIMP-2 binding 
Figure 4: The 3A2 Fab reduces both the frequency and the size of melanoma metastatic nodules in mice. A. The 
catalytically active MT1-MMP is expressed in B16F1-mMT1 cells. Left, the status of MMP-2 (gelatin zymography; top panel) and MT1-
MMP (Western blotting with the AB8345 antibody; bottom panel) in B16F1-mock and B16F1-mMT1 cells. Right, the fluorescent MP-3653 
reporter (25 nM) reports the presence of the catalytically active MT1-MMP (green) in B16F1-mMT1 cells but not in B16F1-mock cells. 
DAPI (blue). Scale bar, 10 μm. B. Schematic representation of our injection protocol. Athymic mice received a single tail vein injection 
of B16F1-mock or B16F1-mMT1 on day 1 followed by the intraperitoneal injection of the 3A2 Fab (10-15 mg/kg) on days 1-12. Mice 
were euthanized and the lungs harvested on day 23. C, Top, representative images of the lungs obtained from the intact control (normal), 
B16F1-mock (mock), B16F1-mMT1 (mMT1) and B16F1-mMT1+3A2 animal groups (mMT1+3A2). Scale bar, 5 mm. Bottom, Western 
blotting (WB) of the lung extracts (20 μg total protein each) using the MT1-MMP AB8345 antibody. D. The weight and the number of the 
pulmonary metastatic lesions in the B16F1-mock, B16F1-mMT1 and B16F1-mMT1+3A2 mice. Normal, the lungs from the intact mice 
control. **, P < 0.05; NS, not significant.
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site in the MT1-CAT molecule with that of the 3A2 and 
DX2400 antibodies. For these purposes, we developed 
several competitive ELISA methodologies. In the 3A2/
TIMP-2 ELISA, the 3A2 Fab was coated on plastic and 
then allowed to bind to the constant amount of MT1-CAT 
jointly with the increasing levels of TIMP-2. The bound 
MT1-CAT was then measured using the rabbit MT1-MMP 
antibody followed by the horseradish peroxidase (HRP)-
conjugated donkey anti-rabbit IgG. We observed that 
TIMP-2, in a dose-dependent manner, competed with the 
3A2 Fab for the binding to MT1-CAT. However, even at a 
high, 80:1, TIMP-2 - MT1-CAT molar ratio, TIMP-2 was 
incapable of fully outcompeting the binding of the 3A2 
Fab to MT1-CAT, thus implying that there was a partial 
overlap between the TIMP-2 and the 3A2 binding regions 
(Figure 5A). Similar observations were obtained in our 
DX2400/TIMP-2 ELISA that employed the immobilized 
DX2400 Fab (Figure 5A), suggesting an overlap among 
the TIMP-2 and the 3A2 and DX2400 binding regions 
in MT1-CAT. Our additional 3A2/DX2400 ELISA, in 
which the immobilized 3A2 Fab was allowed to bind 
to the constant amount of MT1-CAT jointly with the 
increasing concentrations of DX2400 Fab, confirmed 
that the DX2400 Fab, in a dose-dependent manner, albeit 
only partially, also competed the 3A2 antibody binding to 
MT1-CAT (Figure 5A).
Figure 5: The 3A2 Fab antibody competes with TIMP-2, but not with hydroxamate inhibitor, for its binding to MT1-
MMP. A. The 3A2 and DX2400 Fab antibodies compete between themselves and also with TIMP-2 for their binding to MT1-MMP. 3A2/
TIMP-2 and DX/TIMP-2, ELISA results in which the immobilized 3A2 and DX2400 Fab antibodies were each co-incubated with MT1-
CAT (25 nM) and the indicated TIMP-2 – MT1-CAT molar ratios. 3A2/DX and 3A2/GM6001, ELISA results in which the immobilized 
3A2 was co-incubated with MT1-CAT (25 nM) and the indicated DX2400 Fab or GM6001 – MT1-CAT molar ratio, respectively. In each 
ELISA, the bound MT1-MMP was then quantified using the rabbit polyclonal MT1-MMP antibody followed by the HRP-conjugated 
donkey anti-rabbit IgG and a TMB/E substrate. No MT1, MT1-CAT was not added. MT1, only MT1-CAT (25 nM) was added (=100%). 
Data are means ± SE from three individual experiments conducted in triplicate. **, P < 0.05. B. The 3A2 and DX2400 antibodies do not 
directly interact with the catalytic zinc vicinity. Left, the fluorescent MP-3653 reporter (25 nM) with a hydroxamate warhead did not detect 
the catalytically active MT1-MMP in MT1-MMP-deficient MCF7-mock cells. Right panels, MCF7-MT1 cells were left alone (no inhibitor) 
or co-incubated with the fluorescent MP-3653 reporter (25 nM) alone or jointly with the 3A2 Fab, the DX2400 Fab or IgG, the 3G4 IgG 
control, TIMP-1 (1,000 nM, each), TIMP-2 (50 nM) and GM6001 (100 nM). Scale bar, 10 µm. DX, DX2400.
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3A2 Fab does not directly interact with the active 
site zinc in MT1-MMP
We next determined if the 3A2 and DX2400 
inhibitory mechanism resembles that of TIMP-2 and 
hydroxamate inhibitors, both of which directly interact 
with the active site Zn2+ binding motif HEXXHXXGXXH 
in MT1-MMP [54-56]. Our 3A2/GM6001 ELISA in 
which the immobilized 3A2 Fab was allowed to bind to 
the constant concentration of MT1-CAT supplemented 
with the increasing concentrations of GM6001 revealed 
that, even at an exceedingly high, 400:1 GM6001 - MT1-
CAT molar ratio, the binding of the 3A2 Fab to MT1-CAT 
remained unaffected (Figure 5A). This suggests that the 
3A2 Fab does not interact directly with the catalytic Zn 
binding motif in the MT1-MMP active site.
To corroborate these results, we next determined 
if the 3A2 and DX2400 antibodies were able to affect 
the binding of the fluorescent hydroxamate-based MP-
3653 reporter to cellular MT1-MMP [53]. Because of 
the steric hindrance between the antibody and bulky 
liposome-based reporter, we expected that the antibody 
binding would limit the concurrent binding of the reporter 
hydroxamate warhead to the MT1-MMP active site. In 
these binding experiments, we used breast carcinoma 
MCF7-MT1 cells stably transfected with MT1-MMP and 
the control MT1-MMP-deficient MCF7-mock cells. Cells 
were co-incubated with the MP-3653 reporter alone or 
jointly with the 3A2 Fab or the DX2400 in its Fab or 
IgG format. As controls, cells were co-incubated with the 
reporter in the presence of TIMP-1, TIMP-2, GM6001 
or the non-inhibitory MT1-MMP 3G4 IgG antibody. The 
MP-3653 reporter readily bound to cell surface-associated 
MT1-MMP in the untreated MCF7-MT1 cells but not in 
MCF7-mock cells (Figure 5B). Both TIMP-2 (at a 2:1 
inhibitor - reporter molar ratio) and GM6001 (at a 4:1 
hydroxamate - reporter molar ratio) totally abolished the 
binding of the reporter to MCF7-MT1 cells, while TIMP-
1 (even at a high, 40:1 inhibitor - reporter molar ratio) 
was inactive. In agreement, the non-inhibitory MT1-
MMP 3G4 antibody also did not affect the binding of 
the reporter to MCF7-MT1 cells. To our surprise, neither 
the DX2400 Fab or IgG, nor the 3A2 Fab exhibited 
any significant repression of the MP-3653 reporter 
fluorescence in MCF7-MT1 cells. The 3A2 Fab size (≈ 75 
Å in length, ≈ 50 Å in width) is >100-fold less compared 
with the 10 nm PEG-5000 spacer [57] of the liposome-
based reporter (Supplementary Figure S3). The PEG-5000 
spacer of the MP-3653 reporter is functionalized with 
the hydroxamate warhead which chelates the active site 
catalytic zinc in MT1-MMP. Accordingly, it is reasonable 
to expect that the hydroxamate warhead binding to the 
catalytic zinc did not provide any steric hindrance for 
TIMP-2, and, accordingly, for the 3A2 or DX2400 Fab 
antibodies. These results, especially if combined with our 
competitive ELISA tests, suggested that, in contrast with 
TIMP-2 and hydroxamate inhibitors, the inhibitory 3A2 
and DX2400 antibodies caused MT1-MMP inactivation 
without any deep penetration into the active site cavity 
and without direct interference with the catalytic zinc ion.
Modeling of interactions of the 3A2 Fab with 
MT1-MMP
The results of our binding and competition 
experiments, and the availability of the X-ray structures 
of multiple human antibodies, TIMP-2, MT1-MMP and 
MT1-MMP•TIMP-2 complex stimulated us to build a 
crude model of the 3A2 Fab - MT1-CAT interactions. 
To estimate the space occupied by the 3A2 Fab and 
TIMP-2 relative to MT1-CAT, we used as templates the 
structures of the MT1-MMP•TIMP-2 complex (PDB 
1BQQ), of an anti-TDRD3 Fab complexed with the 
tudor domain of human TDRD3 (PDB 3PNW) and of 
GM6001 bound to the anthrax toxin lethal factor (PDB 
4PKW). To model the 3A2 Fab structure, we used the 
residue sequences of the VL and VH chains of the anti-
TDRD3 Fab [58] as a template. We next replaced the 
original anti-TDRD3 sequences Y91GYPI95 in VL CDR-L3, 
F29SSSSI34 in VH CDR-H1, S
50ISSSYGYTY59 in VH 
CDR-H2 and T99VRGSKKPYFSGWAMDY115 in VH 
CDR-H3 with the respective VL and VH CDR sequences 
of the 3A2 Fab (SSYSLIT, LSYSSM, SIYPYSGYTY 
and VKLQKDKSHQWIRNLVATPYGRYVMDY, 
respectively) (Table 1).
Earlier we reported that the binding of the 3A2 
Fab to MT1-CAT was affected by the F260A mutation 
in the MT1-MMP sequence. Other mutations, including 
T190A, F198A, Y203A, F204A and N231A (all 
residues are within a 15 Å distance from the catalytic 
Zn2+ atom), did not affect the antibody binding to the 
protease (Supplementary Figure S1) (submitted). These 
data allowed us to restrict the docking area in MT1-
MMP. Accordingly, we selected the N225EDLN229, 
S250SDPS254 and F260YQWMDTEN268 surface regions in 
the MT1-MMP structure as the 3A2 potential epitopes. 
Conversely, the SSYSLIT, LSYSSM, SIYPYSGYTY 
and VKLQKDKSHQWIRNLVATPYGRYVMDY VL and 
VH CDR sequences represented the potential 3A2 Fab 
paratopes.
We then modeled a putative quadri-molecular 
complex that involved TIMP-2, GM6001, MT1-CAT and 
the designed 3A2 Fab. According to our modeling, the 
top scored position indicated that there was an overlap of 
the 3A2 Fab moiety with the space occupied by TIMP-
2 in the MT1-MMP molecule (Figure 6A). These results 
correlated well with the partial competition between 
TIMP-2 and the 3A2 Fab we observed in our competitive 
ELISA assays (Figure 5A). Our model also indicated that 
TIMP-2, but not the 3A2 Fab, interacted with the catalytic 
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Table 1: The modified complementary determining regions (CDR) sequences in the light (L) and the heavy (H) 
chains of the 3A2 Fab





Figure 6: The 3A2 Fab competes with TIMP-2 binding to MT1-CAT. A. The predicted structure of the hypothetical MT1-
CAT•TIMP-2•3A2 Fab•GM6001 quadri-molecular complex. MT1-CAT is shown as cartoon (green), TIMP-2 and the 3A2 Fab are shown as 
yellow and cyan surfaces. GM6001, red sticks; the Phe260 residue of the MT1-CAT sequence, black sticks; the catalytic and structural zinc 
ions in MT1-CAT, black and grey spheres, respectively; the structural calcium ion, green sphere. A putative region where TIMP-2 clashes 
with the 3A2 moiety is shown in purple. The figure summarizes a detailed superimposition analysis of the available crystal structures of 
the tudor domain of human TDRD3 in complex with an anti-TDRD3 Fab (PDB 3PNW), MT1-CAT complexed with TIMP-2 (PDB 1BQQ) 
and the anthrax toxin lethal factor bound to GM6001 (PDB 4PKW). B, Unlike TIMP-2, the 3A2 Fab does not bind to the catalytic zinc 
vicinity in MT1-MMP. Left, close-up of the hypothetical MT1-CAT•TIMP-2•GM6001 complex shows that the bound GM6001 penetrates 
into the space occupied by TIMP-2 [46, 48, 49]. As a result, TIMP-2 and GM6001 compete for their binding to MT1-MMP. Right, two 
rotated close-ups of the MT1-CAT•3A2 Fab •GM6001 complex clearly indicate that the 3A2 Fab cannot interact with the catalytic zinc 
vicinity (black sphere) in the MT1-MMP active site. As a result, the 3A2 Fab did not compete with GM6001 for the binding to MT1-CAT.
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Zn2+ in the MT1-MMP core, and, as a result, there was an 
expected overlap of GM6001 with the TIMP-2 structure 
(Figure 6B). These observations are in agreement with the 
results by others [29, 54-56] as well as the data from our 
ELISA and cell-based tests (Figure 5A, 5B). To validate 
these data, we are currently in the process of transforming 
the 3A2 Fab into its full-length IgG format. We will then 
determine the crystal structure of the MT1-CAT•3A2 IgG 
complex to better understand the molecular mechanism of 
MT1-MMP inhibition by the 3A2 antibody.
DISCUSSION
Proteases, including MMPs, are both valuable 
diagnostic markers and pharmacological targets. 
Accordingly, the MMP inhibitors are expected to be 
valuable drugs in multiple pathologies and, especially 
in cancer. Ubiquitous pro-invasive MT1-MMP is an 
archetype membrane-associated MMP and a focus of 
numerous extensive studies leading to an appreciation 
of this protease key functions in cell migration and 
metastasis [59]. Naturally, this cell surface-associated 
protease gradually became a promising drug target. 
However, because of homology in the active site region of 
MMPs, the small-molecule active site-targeting inhibitors 
(primarily, hydroxamates that chelate the catalytic zinc 
atom in the MMP active site) cross-reacted with multiple 
MMPs rather than with MT1-MMP alone [29]. Off-target 
effects and low net efficacy of these inhibitors caused in 
their failure in clinical trials [30-32]. As a result, it is now 
broadly accepted that high level of specificity is required 
for pharmacological targeting of MT1-MMP.
Accordingly, high selectivity is a key parameter in a 
design of a successful anti-MT1-MMP therapy. Function-
blocking antibodies represent a valuable alternative to 
small-molecule MMP inhibitors. Several MT1-MMP 
antibodies, both murine and human, have been recently 
developed and partially characterized [17, 34-36, 40, 41]. 
All of these antibodies target the exosites rather than the 
catalytic site region of MT1-MMP. Antibody targeting of 
the active site region that is buried in the MMP globule is 
a challenge, especially if the conventional approaches are 
employed in the library construction and antibody design.
To overcome this challenge, we designed a human 
Fab antibody library in which the antibody constructs 
exhibited the long, 23-27 residue, VH CDR-H3 [43]. 
The length of these CDR significantly exceeded that (9-
12 residues) in human and murine antibodies [60] and 
correlated with an average CDR size recorded in the 
camelid antibodies [61]. Using MT1-CAT as bait, we 
identified over 20 binders from which 14 performed as 
inhibitors of MT1-MMP rather than as broad-specificity 
antagonists. The most efficient and selective inhibitor 
was the 3A2 Fab that we extensively characterized and 
reported here.
Our binding and inhibitory in vitro and cell-
based tests and assays convincingly demonstrated 
that the 3A2 antibody is both an efficient and selective 
inhibitor of cellular MT1-MMP rather than a broad-
specificity MMP inhibitor. According to our tests, the 
selectivity and efficiency of the 3A2 Fab was similar to 
that of the DX2400 Fab, the most potent and selective 
human function-blocking anti-MT1-MMP antibody. The 
conversion of the DX2400 Fab into the full-length human 
IgG caused a further 10-fold increase in the antibody 
potency. Therefore, we expect that a similar improvement 
would take place with the 3A2 Fab fragment, suggesting 
that the 3A2 Fab is a very promising lead antibody against 
pro-tumorigenic/metastatic MT1-MMP.
Interestingly, the 3A2 antibody binding mode was 
dissimilar from that of hydroxamates that chelate the 
active site catalytic zinc in MT1-MMP and of natural 
protein inhibitors (such as TIMP-2) the inhibitory loop 
of which penetrates deeply into the protease active site 
pocket [54-56]. According to our binding, competition 
and modeling studies, the 3A2 Fab epitope only partially 
overlaps with the TIMP-2 binding site in the MT1-MMP 
catalytic domain and does not reach out to the catalytic 
zinc proximity. We believe that our modeling provided 
a structural rationale for our experimental results and 
sharpened a focus for our on-going mutagenesis and 
antibody fine-tuning efforts. Taken together, our studies 
generated a roadmap for the subsequent mutagenesis and 
structure-based affinity maturation of the 3A2 antibody.
Furthermore, because of its selectivity and 
low nanomolar inhibitory potency, the 3A2 antibody 
represents a valuable tool for the analysis of the MT1-
MMP functional significance in cancer. Earlier work 
by others demonstrated that in a model of advanced 
peritoneal ovarian cancer, MT1-MMP-dependent 
invasion and metastasis was effectively inhibited by 
i.p. administration of the anti-MT1-MMP monoclonal 
antibody [17]. Similarly, another selective, albeit 
distinct, anti-MT1-MMP monoclonal antibody repressed 
metastasis of breast carcinoma MDA-MB-231 cells in 
a mouse orthotopic xenograft model [34]. We then used 
the 3A2 Fab to assess if the low, 10-15 mg/kg, antibody 
amount affected the development of metastatic lesions in 
the experimental pulmonary melanoma metastasis model 
in mice. Our results provided experimental evidence that 
the anti-MT1-MMP monotherapy caused a significant 
reduction in both the number and the size of melanoma 
pulmonary metastases. Our results, especially if combined 
with the results by others [11-13, 19], suggest that MT1-
MMP plays the most critical role in the metastatic 
invasion rather than in tumor development and growth. 
Accordingly, we now believe that therapeutic targeting of 
MT1-MMP would be most beneficial for patients suffering 
from metastatic cancer and that our data would contribute 




The reagents were purchased from Sigma-
Aldrich (St. Louis, MO) unless indicated otherwise. 
The [(7-methoxycoumarin-4-yl)acetyl]-Pro-Leu-Gly-
Leu- [N-3-(2,4-dinitrophenyl)-L-α,β-diaminopropionyl]-
Ala-Arg-NH2 (MCA-PLGL-Dpa-AR-NH2) fluorogenic 
substrate was acquired from R&D Systems (Minneapolis, 
MN). Both murine monoclonal and rabbit polyclonal 
MT1-MMP antibodies (3G4 and AB8345, respectively), 
human α1-antitrypsin (AAT) and a broad spectrum 
hydroxamate inhibitor of MMPs (GM6001) were 
purchased from EMD Millipore (Temecula, CA). TMB/E 
substrate was from SurModics (Eden Prairie, MN). The 
mammary epithelial cell growth medium (MEGM) that 
included a bovine pituitary extract supplement and DMEM 
were from Lonza (Walkersville, MD) and Thermo Fisher 
Scientific (Waltham, MA), respectively. The MT1-MMP 
MP-3653 fluorescent reporter that exhibited an inhibitory 
hydroxamate warhead was described earlier [53]. Human 
TIMP-1 was purchased from Life Technologies (Carlsbad, 
CA). The DX2400 function-blocking human full-length 
IgG1 (DX2400 IgG) antibody was kindly provided to us 
by Kadmon (New York, NY).
Cells
Human breast carcinoma MCF-7, fibrosarcoma 
HT1080 and mammary epithelial 184B5 cells were 
obtained from ATCC (Manassas, VA). Mouse melanoma 
B16F1 cells were a generous gift by Ralph A. Reisfeld (The 
Scripps Research Institute, La Jolla, CA). MCF-7, HT1080 
and B16F1 cells were routinely maintained in DMEM 
supplemented with 10% FBS and gentamicin (10 μg/
ml). Both B16F1 cells stably transfected with the original 
pcDNA3-zeo vector (B16F1-mock cells) or the pcDNA3-
zeo plasmid encoding the full-length murine MT1-MMP 
proenzyme (B16F1-mMT1 cells) and both MCF-7 cells 
stably transfected with the empty pcDNA3-zeo vector 
(MCF7-mock cells) or the pcDNA3-zeo plasmid encoding 
the full-length human MT1-MMP (MCF7-MT1 cells) 
were obtained earlier [62, 63]. 184B5 cells were routinely 
maintained in MEGM-5% FBS supplemented with bovine 
pituitary extract (26 µg/ml) and gentamicin. 184B5 cells 
stably transfected with the original pLenti6/V5-D-TOPO 
lentiviral vector (184B5-mock cells) or the lentiviral vector 
encoding the MT1-MMP C-terminally tagged with a V5 tag 
(185B5-MT1 cells) were constructed earlier [51].
Expression and purification of TIMP-2 and 
MMPs
The cloning, expression and purification of the 
recombinant human TIMP-2 was performed as previously 
described [53]. The TIMP-2-free proMMP-2 zymogen 
was isolated from the p2AHT1A72 cells (a derivative 
of HT1080 cells transfected with both the adenoviral 
E1A gene and the full-length MMP-2 cDNA) [50]. The 
individual catalytic domains (CAT) of human MT1-MMP, 
MT2-MMP, MT3-MMP, MT4-MMP, MT5-MMP and 
MT6-MMP were expressed in E. coli One Shot BL21 
Star (DE3) (Thermo Fisher Scientific). The purified 
proteases were then isolated from the inclusion bodies 
using metal-chelating chromatography and refolded to 
restore their native conformation [45]. Only the samples 
with the purity >95% were used in our subsequent studies. 
The refolded MT-MMPs were readily used in activity 
assays. The concentration of the catalytically active 
MT-MMP samples was measured using a fluorescent 
assay by titration against a standard GM6001 solution of 
known concentration and Mca-PLGL-Dpa-AR-NH2 as a 
substrate. The steady-state rate of the substrate cleavage 
was plotted as a function of inhibitor concentration and 
fitted with the equation V=SA(E0−A(E{(E0+I+Ki)−[(E0+I
+Ki)
2−E(0I]
0.5}), where V, SA, E0, I and Ki are the steady-
state rate of substrate hydrolysis, specific activity (rate per 
unit of MMP concentration), MT-MMP concentration, 
inhibitor concentration and the dissociation constant of the 
MT-MMP•inhibitor complex, respectively [64, 65].
Purified Fab fragments
The cloning, expression and isolation of the 
DX2400 Fab fragment was reported earlier [66]. Both 
the DX2400 full-length IgG and Fab samples were used 
in our experiments for comparison purposes. From the 
twenty purified human Fab constructs that were capable 
of binding to MT1-MMP (submitted), the 2B5, 3A2, 3B10 
and 3E9 Fab constructs were further characterized in this 
study.
Protease inhibition assay
The cleavage assay was performed in triplicate in 
wells of a 96-well plate using the purified individual CAT 
of MMPs (5 nM) and the fluorescent peptide Mca-PLGL-
Dpa-AR-NH2 substrate (1 µM) in 0.2 ml 50 mM HEPES, 
pH 7.5, containing 10 mM CaCl2, 0.5 mM MgCl2 and 10 
μM ZnCl2. Prior to the reactions, increasing concentrations 
of the Fab antibodies (0-5,000 nM) were co-incubated with 
the protease samples for 30 min at ambient temperature. 
Initial reaction velocity was monitored continuously 
at λex=320 nm and λem=400 nm using a fluorescence 
spectrophotometer. The IC50 values were calculated by 
determining the inhibitor concentrations that inhibited the 
cleavage activity by 50%. SigmaPlot was used as fitting 
software.
Cleavage of AAT
The cleavage reactions (20 μl each, 1 h at 37°C) 
contained AAT (2 µg, ≈2 μM) and MT1-CAT (40 nM, 1:50 
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enzyme-substrate molar ratio) in 50 mM HEPES, pH 7.5, 
supplemented with 10 mM CaCl2 and 50 μM ZnCl2. Where 
indicated, the Fab antibodies (20-200 nM), TIMP-1 (1,000 
nM), TIMP-2 (20 nM) or GM6001 (1,000 nM) were added 
to the reactions. The reactions were stopped using 5% 
SDS and analyzed by SDS-PAGE in a 4-12% gradient 
NuPAGE-MOPS gel (Life Technologies) followed by 
Coomassie Blue R250 staining.
Cell viability assays
Assays were conducted in wells of a 96-well flat 
bottom, white wall plates. 184B5 and B16F1-mMT cells 
(7.5×104) were grown for 16 h in MEGM-5% FBS and 
DMEM-10% FBS, respectively. After washing with 
PBS, fresh FBS-free medium (0.1 ml) containing the 
Fab antibodies (1,000 nM) was added to the cells and 
incubation was continued for an additional 24 h. The 
viable cells were then counted using a luminescent ATP-
Lite assay (PerkinElmer; Waltham, MA). Each datum 
point represents the results of at least 2 independent 
experiments performed in triplicate.
MMP-2 gelatin zymography and Western 
blotting
Following incubation of the cells (1×105/well of a 
48-well plate) in serum-free medium (150 µl), the status 
of MMP-2 was analyzed by gelatin zymography of the 
medium aliquots (15 μl) using precast 10% acrylamide 
gels co-polymerized with 0.1% gelatin (Life Technologies) 
as described previously [53]. To stimulate the MMP-2 
activation, HT1080 cells (1×105) were stimulated for 24 
h using phorbol 12-myristate 13-acetate (50 ng/ml) with 
or without the presence of the Fab antibodies (20-200 
nM), TIMP-1 (1,000 nM), TIMP-2 (100 nM) or GM6001 
(1,000 nM). We also used the B16F1-mMT1 cells that 
expressed the murine MT1-MMP and the respective 
control B16F1-mock cells transfected with the original 
plasmid alone. In the latter, cells (1×105) were seeded for 
24 h in DMEM-10% FBS in wells of a 48-well plate. Cells 
were replenished with fresh DMEM (150 µl) containing 
purified proMMP-2 (5-10 nM) alone or jointly with the 
Fab antibodies (25-200 nM) or GM6001 (1,000 nM). 
In 18 h, the medium aliquots (15 μl) were analyzed by 
gelatin zymography, while cells were washed with PBS 
and then lysed in TBS containing 50 mM N-octyl-β-D-
glucopyranoside, 1 mM phenylmethylsulphonyl fluoride, 
10 mM EDTA, and a protease inhibitor cocktail set 
III. Insoluble material was removed by centrifugation 
(14,000×g; 30 min). The supernatant aliquots (5 μg total 
proteins) were separated by electrophoresis in a 4–12% 
gradient NuPAGE-MOPS gel (Life Technologies) and 
analyzed by Western blotting with the MT1-MMP AB8345 
antibody followed by the secondary HRP-conjugated 
antibody (Jackson ImmunoResearch; West Grove, PA) 
and a SuperSignal West Dura Extended Duration Substrate 
kit (Thermo Fisher Scientific). Where indicated, the 
images were digitized and the intensity of the bands was 
quantified using ImageJ software. These data were used 
to measure the zymogen:activation intermediate ratio of 
MMP-2 expressed as a percentage of the zymogen and 
the activation intermediate each related to their combined 
total amount.
COL-I degradation assay
The assay was performed in triplicate in wells of 
a 24-well plate. Wells were coated for 4 h at 37°C with 
neutralized, chilled rat tail COL-I (300 µg/ml, 350 µl in 
PBS) and then air dried for 16 h. The COL-I coating was 
washed twice for 30 min at ambient temperature with sterile 
H2O and rehydrated for 2 h at 37°C in 0.4 ml DMEM. 
Seeded cells (1×105) were allowed to attach for 4 h. Fresh 
DMEM (0.4 ml) containing the 3A2 Fab (200 nM), the 
DX2400 Fab or IgG antibodies (100-200 nM), TIMP-1 
(1,000 nM), TIMP-2 (100 nM) or GM6001 (1,000 nM) was 
then added to the cells. At day 3, cells were replenished with 
fresh medium supplemented with the respective inhibitors 
and incubation was continued for an additional 2 days. Cells 
were next detached with 0.25% trypsin/0.5 mM EDTA. 
COL-I was fixed using 4% p-formaldehyde and stained 
with Coomassie Blue R250. The images were captured 
using a Nikon TE-2000 microscope with a ×20 objective 
and a CCD camera. COL-I degradation appeared as clear 
zones in the blue background.
Cell invasion assays
The assays were conducted in wells of a 24-well, 8 
μm pore size Transwell plate (Corning; Corning, NY). A 6.5-
mm insert membrane was coated using 0.1 ml rat tail COL-I 
(0.3 mg/ml; BD Biosciences; Franklin Lakes, NJ), air dried 
for 16-18 h and then rehydrated for 1 h in 0.2 ml DMEM. 
The inner/lower chamber contained DMEM-10% FBS as 
a chemoattractant. The cells (1×105) were co-incubated for 
60 min in DMEM alone or supplemented with the 3A2 and 
DX2400 Fab fragments (500 nM, each), DX2400 IgG (50-
200 nM) or GM6001 (1,000 nM) prior to plating cells into 
the outer/upper chamber. The inhibitor concentration was 
identical in both the outer and inner chambers. The cells 
were allowed to migrate for 16-18 h. The cells were then 
removed from the membrane top surface using a cotton 
swab. The cells on the membrane bottom surface were fixed 
and stained using 0.2% crystal violet-20% methanol. The 
incorporated dye was extracted using 1% SDS and the A590 
of the extract was measured using a microplate reader. Data 
are means ± SE from 3 individual experiments conducted in 
triplicate. Cell invasion level was calculated relative to the 
intact 184B5-MT1 cells (=100%).
Oncotarget2795www.impactjournals.com/oncotarget
Biotinylation of MT1-CAT
The refolded MT1-CAT aliquot (0.2 mg/ml in 0.7 ml 
50 mM HEPES pH 7.5) was labeled for 30 min on ice at a 
1:20 enzyme-biotin molar ratio using EZ-Link sulfo-NHS-
LC-biotin (Thermo Fisher Scientific). Excess biotin was 
removed using a 0.7-ml protein desalting spin-column.
Fab antibody binding to MT1-CAT measured by 
ELISA
The wells of a 96-well Maxisorp ELISA plate (Nunc; 
Rochester, NY) were coated with Streptavidin (3 μg/ml, 125 
μl 15 mM bicarbonate buffer, pH 9.6) at 4°C for 18 h, then 
blocked with 0.5% gelatin in TBS-0.075% Tween (TBS/T) 
for 1 h at 37°C. Following two washes with TBS/T, the plate 
was incubated for 20 min at ambient temperature with the 
biotinylated MT1-CAT sample (25 nM). The unbound MT1-
CAT was removed using multiple washes with TBS/T (5 
min each). Increasing concentrations of the Fab antibodies 
(0-8,000 nM; 50 μl TBS/T-0.5% gelatin) were allowed to 
bind to MT1-CAT for 1 h at ambient temperature. Following 
extensive washing with TBS/T, HRP-conjugated goat anti-
human Fab (dilution 1:10,000; 50 μl TBS/T-0.5% gelatin) was 
added to the wells and incubation continued for an additional 
1 h. Following extensive washing with TBS/T and then with 
H2O, TMB/E substrate (0.1 ml) was added to the wells. The 
reaction was stopped using 1 M H2SO4 (25 µl). The resulting 
A450 values were measured using a plate reader. The Kd values 
were calculated by determining the inhibitor concentrations 
that bound 50% of the MT1-MMP molecules. SigmaPlot was 
used as fitting software. Statistical analyses were performed 
using a two-tailed, unpaired Student’s t-test. P values below 
0.05 were considered significant. Data are means ± SE from 
at least 3 individual experiments performed in triplicate.
Competition between the Fab antibodies and 
TIMP-2 for the binding to MT1-CAT measured 
by ELISA
Wells of a 96-well Maxisorp ELISA plate were 
coated with the 3A2 or DX2400 Fab aliquots (2 μg/ml 
each, 125 μl 15 mM bicarbonate buffer, pH 9.6) at 4°C 
for 18 h and then blocked with 3% BSA in PBS-0.075% 
Tween (PBS/T) for 1 h at 37°C. The follow-on procedures 
were carried out at ambient temperature. Following 
washes with PBS/T, MT1-CAT (25 nM; PBS/T-1% BSA) 
alone or jointly with increasing concentrations of TIMP-
2 (2-2,000 nM), DX2400 Fab (2-2,000 nM) or GM6001 
(10-10,000 nM) was added to the wells and incubation 
continued for 2 h. The unbound material was removed 
using multiple washings in PBS/T (5 min each) and then 
the rabbit MT1-MMP Ab8345 antibody (0.5 µg/ml; 0.1 ml 
PBS/T-1% BSA) was added for 2 h. Following extensive 
washing with PBS/T, the HRP-conjugated donkey anti-
rabbit IgG (1:10,000 dilution, 0.1 ml PBS/T-1% BSA) 
was added to the wells and incubation continued for an 
additional 1 h. After extensive washing with PBS/T and 
then with H2O, TMB/E substrate (0.1 ml) was added 
to the wells. The reaction was stopped by adding 1 M 
H2SO4 (0.1 ml) and the resulting A450 value was measured 
using a plate reader. Data are means ± SE from at least 3 
individual experiments performed in triplicate.
Cell-based assay using the fluorescent MP-3653 
reporter
Cells were plated in DMEM-10% FBS on a 15-mm 
glass coverslip and allowed to reach a 25-50% confluency. 
The cells were then washed in PBS and co-incubated for 
30 min at 37°C in DMEM supplemented with either 0.2% 
BSA alone or jointly with the 3A2 Fab, the DX2400 Fab 
or IgG format, the 3G4 IgG control, TIMP-1 (1,000 nM, 
each), TIMP-2 (50 nM) or GM6001 (100 nM). The MP-
3653 reporter (25 nM) was next added to the cells and 
incubation continued for an additional 3 h. Cells were then 
washed in PBS and fixed in 4% p-formaldehyde, mounted 
in the VectaShield mounting medium containing DAPI for 
the nuclear staining (Vector Lab; Burlingame, CA) and 
examined using a fluorescence microscope equipped with 
a digital camera.
Melanoma pulmonary metastasis in mice
To readily develop pulmonary metastatic lesions, 
at day 1, 5-6 week-old female athymic Foxn1nu nude 
mice (Envigo; Indianapolis, IN) received a single tail 
vein injection of B16F1-mock and B16F1-mMT1 
cells [0.2x106 in 0.2 ml Hank’s Balanced Salt Solution 
(HBSS)] [62, 67]. Six and twelve animals received 
B16F1-mock and B16F1-mMT1 cells, respectively. 
Additional 3 mice were left intact and served as a control 
for normal behavior and the normal lung weight. At day 
1, 3, 5, 8 and 12, six animals from the B16F1-mMT1 
group also received an intraperitoneal injection (i.p.) of 
the 3A2 Fab (10-15 mg/kg in 150 µl HBSS), while other 
mice received the vehicle alone. At day 23, mice were 
euthanized according to the NIH guidelines. The lungs 
were harvested, washed in ice-cold PBS and weighed. 
For each mouse, the lungs were photographed and then 
sectioned (Supplementary Figure S2A-S2C). Metastatic 
nodules were counted using the digitized lobe images. 
The lung samples were next snap-frozen. The sections 
(0.15 mg each) of the lungs were extracted in 0.9 ml 20 
mM Tris-HCl, pH 7.4, supplemented with 150 mM NaCl, 
0.5% deoxycholate, 1% IGEPAL, 1% Triton X-100, 
0.1% SDS, a protease inhibitor cocktail set III, 1 mM 
phenylmethylsulfonyl fluoride, 10 mM EDTA and 10 µM 
GM6001. The solubilized material was separated from 
the pellet by centrifugation (14,000×g; 30 min). The 
protein concentration was then adjusted in the samples 
to reach 3 mg/ml. Sample aliquots (20 μg total protein 
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each) were then analyzed by Western blotting with the 
MT1-MMP AB8345 antibody followed by the secondary 
HRP-conjugated antibody and a SuperSignal West Dura 
Extended Duration Substrate kit. All protocols for animal 
studies were reviewed and approved by the Institutional 
Animal Care and Use Committee at SBP Medical 
Discovery Institute.
Structural modeling
In our modeling studies, we used the crystal 
structure of an anti-TDRD3 Fab in its complex with the 
tudor domain of human TDRD3 (PDB 3PNW) [58], MT1-
CAT complexed with TIMP-2 (PDB 1BQQ) [54] and the 
GM6001 hydroxamate bound to the anthrax toxin lethal 
factor (PDB 4PKW) [68]. The structures were analyzed 
and superimposed using PyMOL. The 3A2 Fab fold was 
engineered using the peptide sequence of the VL and VH 
chains of the anti-TDRD3 Fab [58] as a template. In 
the latter, the sequences VL CDR-L3 (Y
91GYPI95), VH 
CDR-H1 (F29SSSSI34), VH CDR-H2 (S
50ISSSYGYTY59) 
and VH CDR-H3 (T
99VRGSKKPYFSGWAMDY115) were 
replaced by SSYSLIT, LSYSSM, SIYPYSGYTY and 
VKLQKDKSHQWIRNLVATPYGRYVMDY, respectively 
(Table 1). We then combined the structure of the VL and 
VH chains from 3PNW with the structure of the modified 
CDR-L3, CDR-H1, CDR-H2 and CDR-H3 regions. The 
structure of the modified CDR regions was modeled using 
the server version of the Modeller program available from 
ModBase [69] and the crystal structure of human prolactin 
receptor complexed with Fab (PDB 4I18) [70]. Using the 
FATCAT program [71], the modeled VH chain of the 3A2 
Fab was then reoriented to the position of the VH chain 
present in the 3PNW structure. The resulting structure 
was then used in our docking experiments. The protein-
protein docking was performed using ZDOCK on-line 
server [72]. For restricting docking area of MT1-MMP 
with the 3A2 Fab, we selected N225EDLN229, S250SDPS254 
and F260YQWMDTEN268 sequences as MT1-MMP 
epitopes and the SSYSLIT, LSYSSM, SIYPYSGYTY and 
VKLQKDKSHQWIRNLVATPYGRYVMDY modified 
sequences in both CDRs VL and VH chains of the Fab as 
paratopes. Figure 6 shows the top scored, most probable 
relative fold of the hypothetical MT1-MMP•TIMP-2•3A2 
Fab•GM6001 quadri-molecular complex.
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